I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents Washington, D.C. 20231

PATENT 18062G002010

Attorney Docket No.: 18062G002010



on 6-4-01
By: Frida Shaffer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jonathan A. Ellman, et al.

Application No.: 09/534,706

Filed: March 23, 2000

For: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS USING ASPARTYL PROTEASE

INHIBITORS

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231 Examiner:

T. McKenzie

Art Unit:

1624

SECOND REQUEST FOR CORRECTED FILING RECEIPT

SEP 0 6 2001
TECH CENTER 1600/2900

Sir:

Attached is a copy of the REQUEST FOR CORRECTED FILING RECEIPT mailed to the Patent and Trademark Office on August 24, 2000, along with a copy of the PTO-stamped postcard showing receipt.

Also attached is a copy of the most recent filing receipt from the Patent and Trademark Office for which issuance of a corrected filing receipt is respectfully requested. Please note that the priority data is still in error.

The correction is not due to any error by applicants, and no fee is due.

Respectfully submitted

genja Garrett Wackowsl

TOWNSEND and TOWNSEND and CREWAL

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834 Tel: (415) 576-0200, Fax: (415) 576-0300

EGW/lls SF 1231409 v1



UNITED STATES PATENT AND TRADEMARK OFFICE

FILE COPY #

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

CONFIRMATION NO. 2595

Bib Data Sheet									
SERIAL NUMBER 09/534,706		FILING DATE 03/24/2000 RULE	CLASS 514		GROUP ART UNIT 1624		ATTORNEY DOCKET NO. 18062G002010		
APPLICANTS Jonathan A. Ellman, Oakland, CA; Gary Lynch, Irvine, CA;									
Irwin D. Kuntz, Greenbrae, CA; Xiaoning Bi, Irvine, CA; Christina E. Lee, San Francisco, CA; A. Geoffrey Skillman, San Francisco, CA;									
Tasir Haque, El Cerrito, CA; ** CONTINUING DATA **********************************									
WHICH CLAIMS BENEFIT OF 60/036,903 02/04/1997 AND CLAIMS BENEFIT OF 60/125,958 03/24/1999									
** FOREIGN APPLICATIONS ************************************									
IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** SMALL ENTITY ** ** 05/23/2000									
Foreign Priority claimed yes no 35 USC 119 (a-d) conditions yes no Met after met Verified and Acknowledged Examiner's Signature Initials				STATE OR COUNTRY CA	SHEETS TO CLA		IMS	INDEPENDENT CLAIMS 3	
ADDRESS 20350									
TITLE Methods for treating neurodegenerative disorders using aspartyl protease inhibitors									
						All Fees			
FILING FEE RECEIVED 680						1.16 Fees (Filing)			
	FEES: Authority has been g No to charge/ci	redit DEPOSIT ACCOUNT			☐ 1.17 Fees (Processing Ext. of time)				
	No	for following	j:			1.18 Fees (Issue)			
							Other		
						☐ Credit			



SEP 07 2000

PATENT APPLICATION
 FILING ACKNOWLEDGMENT

Mailing Date:

8/24/00

File No.:

18062G-002010

Attorney: EGW/lls

Serial No.

09/534,706

Inventor(s):

Jonathan A. Ellman, et al.

Title:

METHODS FOR TREATING NEURODEGENERATIVE

DISORDERS USING ASPARTYL PROTEASE INHIBITORS

Due Date:

8/24/00

RESPONSE TO NOTICE OF MISSING PARTS w/Petition to extend time; Executed declaration (5 copies); Power of attorney by assignee; Certificate under 37 CFR 3.73(b) w/copy of Assignment; Verified statement claiming small entity status of The Regents of the University of California; Verified statement claiming small entity status of Thuris Corporation; Preliminary amendment; Request for corrected filing receipt; Copy of notice of missing parts

Please stamp the date of receipt of the enclosed documents and return this card to addressee

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents Washington, D.C. 20231

Attorney Docket No.: 18062G002010

JUN 0 7 2001

8-24-00 Sonda Shoffer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jonathan A. Ellman, et al.

Application No.: 09/534,706

Filed: March 23, 2000

For: METHODS FOR TREATING NEURODEGENERATIVE DISORDERS USING ASPARTYL PROTEASE

INHIBITORS

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, D.C. 20231 Examiner:

Not yet assigned

Art Unit:

1611

REQUEST FOR CORRECTED FILING RECEIPT



Sir:

Attached is a copy of the official Filing Receipt received from the Patent and Trademark Office in the above-noted application for which issuance of a corrected filing receipt is respectfully requested.

There is an error in that some of the continuing data is missing and should read as

follows:

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 60/125,958 03/24/99 WHICH CLAIMS BENEFIT OF 09/018,226 02/03/98 AND CLAIMS BENEFIT OF 60/036,903 02/04/97 Attorney Docket No.: 18062G002010 Application No.: 09/534,706

Page 2



The correction is not due to any error by applicants, and no fee is due.

Respectfully submitted

Joseph R. Snyder Reg. No. 39,381

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: (415) 576-0200 Fax: (415) 576-0300

EGW/lls

SF 1121321 v1



*OC000000005136491



1906261-01,201045

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: ASSISTANT SECRETARY AND

COMMISSIONER OF PATENT AND TRACEMARKS Washington, D.C. 20231

APPLICATION NUMBER GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO FILING DATE **DRAWINGS** IND CLAIMS CLAIMS 0 1611 18062G002010 22 03/24/2000 50 3 09/534,706

TOWNSEND AND TOWNSEND AND CREW LLP TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111

Date Mailed: 05/24/2000

SER CHILLIAN SON SON WILL SERVICE STRONG SON WILL SERV Receipt is acknowledged of this nonprovisional Patent Application will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jonathan A. Eliman, Oakland, CA; Gary Lynch, Irvine, CA; Irwin D. Kuntz, Greenbrae, CA; Xiaoning Bi, Irvine, CA; Christina E. Lee, San Francisco, CA; A. Geoffrey Skillman, San Francisco, CA; Tasir Haque, El Cerrito, CA;

BECEINED SI :8 NA OE YAH OO

Continuing Data as Claimed by Applicant

60/125,958 03/24/99 WHICH CLAIMS BENEFIT OF 60/036,903 02/04/1997 09/018,226 02/03/98
AND CLAIMS BENEFIT OF 60/036,903 02/04/1997 09/018,226 AND CLAIMS BENEFIT OF 60/036,903 02/04/97


Foreign Applications

If Required, Foreign Filing License Granted 05/23/2000

Title

Methods for treating neurodegenerative disorders using aspartyl protease inhibitors

Preliminary Class



180626-60201005

UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

www.uspto.gov

APPLICATION NUMBER FILING DATE **GRP ART UNIT** FIL FEE REC'D ATTY.DOCKET.NO **DRAWINGS** TOT CLAIMS IND CLAIMS 09/534,706 1611 03/24/2000 680 18062G002010 22 50 3

20350 TOWNSEND AND TOWNSEND AND CREW LLP TWO EMBARCADERO CENTER **EIGHTH FLOOR** SAN FRANCISCO, CA 94111

FILING RECEIPT

OC00000005391215

Date Mailed: 09/12/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jonathan A. Ellman, Oakland, CA; Gary Lynch, Irvine, CA; Irwin D. Kuntz, Greenbrae, CA; Xiaoning Bi, Irvine, CA; Christina E. Lee, San Francisco, CA; A. Geoffrey Skillman, San Francisco, CA; Tasir Haque, El Cerrito, CA;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/018,226 02/03/1998 WHICH CLAIMS BENEFIT OF 60/036,903 02/04/1997

Foreign Applications

If Required, Foreign Filing License Granted 05/23/2000

** SMALL ENTITY **

Title

Methods for treating neurodegenerative disorders using aspartyl protease inhibitors

Preliminary Class

544

OMASEND

Data entry by : TUTT, TONDENICA Team : OIPE Date: 09/12/2000

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

Page 3 of 4 TECHCENTER TOOLSOO

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CRF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231